Advertisement

The Pathophysiology of Spinal Metastases

  • Daisuke Togawa
  • Kai-Uwe Lewandrowski
Part of the Current Clinical Oncology book series (CCO)

Abstract

The American Cancer Society estimated that more Americans than ever, 1.33 million, were diagnosed with cancer in 2003 (1). Reportedly, metastases develops in two-thirds of cancer patients (2). After the lung and liver, the skeletal system is the third most common site of cancer metastasis (3). These cancer metastases are also the most common skeletal tumors seen by orthopaedists, and the ratio of metastatic lesions to primary bone tumors is 25:1 (4,5). Delamarter et al. (6) reported that only 29 (1.5%) cases had primary neoplasms of the lumbar spine in their study of 1971 patients with neoplastic disease. The prevalence of metastases increases with age. Patients who are 50 yr or older are at greatest risk for the development of metastatic disease. The gender ratio varies for each type of malignancy. However, when all neoplasms with the potential to metastasize are considered, men and women are equally at risk for metastatic lesions.

Keywords

Vertebral Body Spinal Cord Compression Skeletal Metastasis Spinal Metastasis Vertebral Vein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Cancer Society Cancer in America 2003. Web site: http://www.cancer.org/docroot/MED/content. Accessed September 30 2004.
  2. 2.
    Shaw B, Mansfield FL, Borges L. One-stage posterolateral decompression and stabilization for primary and metastatic vertebral tumors in the thoracic and lumbar spine. J Neurosurg 1989; 70:405–410.PubMedGoogle Scholar
  3. 3.
    Boland PJ, Lane JM, Sundaresan N. Metastatic disease of the spine. Clin Orthop 1982; 169:95–102.PubMedGoogle Scholar
  4. 4.
    Francis KC, Hutter RV. Neoplasms of the spine in the aged. Clin Orthop 1963; 26:54–66.PubMedGoogle Scholar
  5. 5.
    Mirra JM. Bone Tumors: Clinical, Radiologic, and Pathologic Correlation. Philadelphia, PA: Lea and Febiger; 1989:1495–1517.Google Scholar
  6. 6.
    Delamarter RB, Sachs BL, Thompson GH, et al. Primary neoplasms of the thoracic and lumbar spine. An analysis of 29 consecutive cases. Clin Orthop 1990; 256:87–100.PubMedGoogle Scholar
  7. 7.
    Krishnamurthy GT, Tubis M, Hiss J, Blahd WH. Distribution pattern of metastatic bone disease. A need for total body skeletal image. JAMA 1977; 237:2504–2506.PubMedCrossRefGoogle Scholar
  8. 8.
    Schaberg J, Gainor BJ. A profile of metastatic carcinoma of the spine. Spine 1985; 10:19–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Black P. Spinal metastasis: current status and recommended guidelines for management. Neurosurgery 1979; 5:726–746.PubMedGoogle Scholar
  10. 10.
    Brihaye J, Ectors P, Lemort M, Van Houtte P. The management of spinal epidural metastases. Adv Tech Stand Neurosurg 1988; 16:121–176.PubMedGoogle Scholar
  11. 11.
    Unni KK. Dahlin’s Bone Tumors: General Aspects and Data on 11,087 Cases. 5th ed. Philadelphia, PA: Lippincott-Raven; 1996.Google Scholar
  12. 12.
    Harrington KD. Metastatic disease of the spine. In: Harrington KD, ed. Orthopaedic Management of Metastatic Bone Disease. St. Louis, MO: C. V. Mosby; 1988:309–383.Google Scholar
  13. 13.
    Berrettoni BA, Carter JR. Mechanisms of cancer metastasis to bone. J Bone Joint Surg Am 1986; 68:308–312.PubMedGoogle Scholar
  14. 14.
    Bhalla SK. Metastatic disease of the spine. Clin Orthop 1970; 73:52–60.PubMedGoogle Scholar
  15. 15.
    Johnston AD. Pathology of metastatic tumors in bone. Clin Orthop 1970; 73:8–32.PubMedGoogle Scholar
  16. 16.
    Clain A. Secondary malignant disease of bone. Br J Cancer 1965; 19:15–29.PubMedGoogle Scholar
  17. 17.
    Habermann ET, Sachs R, Stern RE, Hirsh DM, Anderson WJ. The pathology and treatment of metastatic disease of the femur. Clin Orthop 1982; 169:70–82.PubMedGoogle Scholar
  18. 18.
    Harrington KD. Metastatic disease of the spine. J Bone Joint Surg Am 1986; 68:1110–1115.PubMedGoogle Scholar
  19. 19.
    Milch RA, Changus GW. Response of bone to tumor invasion. Cancer 1956; 9:340–351.PubMedCrossRefGoogle Scholar
  20. 20.
    Millburn L, Hibbs GG, Hendrickson FR. Treatment of spinal cord compression from metastatic carcinoma. Review of literature and presentation of a new method of treatment. Cancer 1968; 21:447–452.PubMedCrossRefGoogle Scholar
  21. 21.
    Nottebaert M, Exner GU, von Hochstetter AR, Schreiber A. Metastatic bone disease from occult carcinoma: a profile. Int Orthop 1989; 13:119–123.PubMedCrossRefGoogle Scholar
  22. 22.
    Viadana E, Cotter R, Pickren JW, Bross ID. An autopsy study of metastatic sites of breast cancer. Cancer Res 1973; 33:179–181.PubMedGoogle Scholar
  23. 23.
    Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1:571–573.CrossRefGoogle Scholar
  24. 24.
    Ewing J. Neoplastic Diseases. 6th ed. Philadelphia, PA: WB Saunders; 1928.Google Scholar
  25. 25.
    Onuigbo WI. Organ selectivity in human cancer metastasis. A review. Oncology 1974; 30:294–303.PubMedCrossRefGoogle Scholar
  26. 26.
    Fisher B, Fisher ER, Feduska N. Trauma and the localization of tumor cells. Cancer 1967; 20:23–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Vernon-Roberts B, Pirie CJ. Healing trabecular microfractures in the bodies of lumbar vertebrae. Ann Rheum Dis 1973; 32:406–412.PubMedCrossRefGoogle Scholar
  28. 28.
    Tanaka M, Fushimi H, Fuji T, Ford JM. Sclerosis of lytic metastatic bone lesions during treatment with pamidronate in a patient with adenocarcinoma of unknown primary site. Eur Spine J 1996; 5:198–200.PubMedCrossRefGoogle Scholar
  29. 29.
    Aoki J, Yamamoto I, Hino M, et al. Sclerotic bone metastasis: radiologic-pathologic correlation. Radiology 1986; 159:127–132.PubMedGoogle Scholar
  30. 30.
    Jonsson B, Petren-Mallmin M, Jonsson H, Jr., Andreasson I, Rauschning W. Pathoanatomical and radiographic findings in spinal breast cancer metastases. J Spinal Disord 1995; 8:26–38.PubMedGoogle Scholar
  31. 31.
    Forbes GS, McLeod RA, Hattery RR. Radiographic manifestations of bone metastases from renal carcinoma. AJR Am J Roentgenol 1977; 129:61–66.PubMedGoogle Scholar
  32. 32.
    Crock HV, Yoshizawa H, Kame SK. Observations on the venous drainage of the human vertebral body. J Bone Joint Surg Br 1973; 55:528–533.PubMedGoogle Scholar
  33. 33.
    Louis R, Ouiminga RM, Obounou D. The azygos or vertebroparietal venous anastomotic system. Bull Assoc Anat (Nancy) 1976; 60:381–397.Google Scholar
  34. 33a.
    Groen RJ, du Toit DF, Phillips FM, et al. Anatomical and pathological considerations in percutaneous vertebroplasty and kyphoplasty: a reappraisal of the vertebral venous system. Spine 2004; 29:1465–1471.PubMedCrossRefGoogle Scholar
  35. 34.
    Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg 1940; 112:138–149.PubMedCrossRefGoogle Scholar
  36. 35.
    Batson OV. The role of the vertebral veins in metastatic processes. Ann Intern Med 1942; 16:38–45.Google Scholar
  37. 36.
    Coman DR, deLong RP. The role of the vertebral venous system in the metastasis of cancer to the spinal column; experiments with tumor cell suspensions in rats and rabbits. Cancer 1951; 4:610–618.PubMedCrossRefGoogle Scholar
  38. 37.
    Nagasaka A, Miyamoto T, Yoshizaki H, et al. Vertebral bone metastasis of small cell carcinoma of lung in a diabetic patient, initially diagnosed as pyogenic vertebral osteomyelitis. Diabetes Res 1993; 22:135–144.PubMedGoogle Scholar
  39. 38.
    Coman DR, deLong RP, Mccutcheon M. Studies on the mechanisms of metastasis; the distribution of tumors in various organs in relation to the distribution of arterial emboli. Cancer Res 1951; 11:648–651.PubMedGoogle Scholar
  40. 39.
    Jaffee WF. Tumors and tumorous conditions of the bones and joints. Philadelphia, PA: Lea and Febiger; 1958.Google Scholar
  41. 40.
    Galasko CS. Mechanisms of bone destruction in the development of skeletal metastases. Nature 1976; 263:507–508.PubMedCrossRefGoogle Scholar
  42. 41.
    Wright RL. Malignant tumors in the spinal extradural space: results of surgical treatment. Ann Surg 1963; 157:227–231.PubMedCrossRefGoogle Scholar
  43. 42.
    Fornasier VL, Horne JG. Metastases to the vertebral column. Cancer 1975; 36:590–594.PubMedCrossRefGoogle Scholar
  44. 43.
    Fornasier VL, Czitrom AA. Collapsed vertebrae: a review of 659 autopsies. Clin Orthop 1978; 131:261–265.PubMedGoogle Scholar
  45. 44.
    Wong DA, Fornasier VL, MacNab I. Spinal metastases: the obvious, the occult, and the impostors. Spine 1990; 15:1–4.PubMedCrossRefGoogle Scholar
  46. 45.
    Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol 1978; 3:40–51.PubMedCrossRefGoogle Scholar
  47. 46.
    Stener B, Henriksson C, Johansson S, Gunterberg B, Pettersson S. Surgical removal of bone and muscle metastases of renal cancer. Acta Orthop Scand 1984; 55:491–500.PubMedCrossRefGoogle Scholar
  48. 47.
    Weinstein JN, Collalto P, Lehmann TR. Long-term follow-up of nonoperatively treated thoracolumbar spine fractures. J Orthop Trauma 1987; 1:152–159.PubMedCrossRefGoogle Scholar
  49. 48.
    Weinstein JN, McLain RF. Primary tumors of the spine. Spine 1987; 12:843–851.PubMedCrossRefGoogle Scholar
  50. 49.
    Mareel M, Vermeulen S, Bracke M. [Molecular mechanism of cancer seeding: adhesion molecules and signal transduction networks]. Verh K Acad Geneeskd Belg 1997; 59:327–351.PubMedGoogle Scholar
  51. 50.
    Chishima T, Miyagi Y, Wang X, et al. Visualization of the metastatic process by green fluorescent protein expression. Anticancer Res 1997; 17:2377–2384.PubMedGoogle Scholar
  52. 51.
    Sastre-Garau X. [How to understand mechanisms of metastases]. Rev Med Interne 1992; 13:115–119.PubMedGoogle Scholar
  53. 52.
    Fidler IJ, Gersten DM, Hart IR. The biology of cancer invasion and metastasis. Adv Cancer Res 1978; 28:149–250.PubMedCrossRefGoogle Scholar
  54. 53.
    Kinsey DL. An experimental study of preferential metastasis. Cancer 1960; 13:674–676.PubMedCrossRefGoogle Scholar
  55. 54.
    Spar IL, Bale WF, Marrack D, et al. 131-I-labeled antibodies to human fibrinogen. Diagnostic studies and therapeutic trials. Cancer 1967; 20:865–870.PubMedCrossRefGoogle Scholar
  56. 55.
    Wood S, Jr. Experimental studies on the spread of cancer, with special reference to fibrinolytic agents and anticoagulants. J Med 1974; 5:7–22.PubMedGoogle Scholar
  57. 56.
    Clark RL. Systemic cancer and the metastatic process. Cancer 1979; 43:790–797.PubMedCrossRefGoogle Scholar
  58. 57.
    Springfield DS. Mechanisms of metastasis. Clin Orthop 1982; 169:15–19.PubMedGoogle Scholar
  59. 58.
    Galasko CS. Skeletal metastases and mammary cancer. Ann R Coll Surg Engl 1972; 50:3–28.PubMedGoogle Scholar
  60. 59.
    Powles TJ, Dowsett M, Easty GC, Easty DM, Neville AM. Breastcancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet 1976; 1:608–610.PubMedCrossRefGoogle Scholar
  61. 60.
    Faccini JM. The mode of growth of experimental metastases in rabbit femora. Virchows Arch A Pathol Anat Histol 1974; 364:249–263.PubMedCrossRefGoogle Scholar
  62. 61.
    Chikazu D, Li X, Kawaguchi H, et al. Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. J Bone Miner Res 2002; 17:1430–1440.PubMedCrossRefGoogle Scholar
  63. 62.
    Nauman EA, Satcher RL, Keaveny TM, Halloran BP, Bikle DD. Osteoblasts respond to pulsatile fluid flow with short-term increases in PGE(2) but no change in mineralization. J Appl Physiol 2001; 90:1849–1854.PubMedGoogle Scholar
  64. 63.
    Higashi S, Ohishi H, Kudo I. Augmented prostaglandin E2 generation resulting from increased activities of cytosolic and secretory phospholipase A2 and induction of cyclooxygenase-2 in interleukin-1 beta-stimulated rat calvarial cells during the mineralizing phase. Inflamm Res 2000; 49:102–111.PubMedCrossRefGoogle Scholar
  65. 64.
    Ho ML, Chang JK, Chuang LY, Hsu HK, Wang GJ. Effects of nonsteroidal anti-inflammatory drugs and prostaglandins on osteoblastic functions. Biochem Pharmacol 1999; 58:983–990.PubMedCrossRefGoogle Scholar
  66. 65.
    Kajii T, Suzuki K, Yoshikawa M, et al. Long-term effects of prostaglandin E2 on the mineralization of a clonal osteoblastic cell line (MC3T3-E1). Arch Oral Biol 1999; 44:233–241.PubMedCrossRefGoogle Scholar
  67. 66.
    Yokozeki M, Afanador E, Nishi M, et al. Smad3 is required for enamel biomineralization. Biochem Biophys Res Commun 2003; 305:684–690.PubMedCrossRefGoogle Scholar
  68. 67.
    Zhang H, Ahmad M, Gronowicz G. Effects of transforming growth factor-beta 1 (TGF-beta1) on in vitro mineralization of human osteoblasts on implant materials. Biomaterials 2003; 24:2013–2020.PubMedCrossRefGoogle Scholar
  69. 68.
    Attia P, Phan GQ, Duray PH, Rosenberg SA. Parathyroid hormone-related protein and hypercalcemia in patients with meta-static melanoma: case report and review. Am J Clin Oncol 2003; 26:42–45.PubMedCrossRefGoogle Scholar
  70. 69.
    Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K. Smad3 promotes alkaline phosphatase activity and mineralization of osteoblastic MC3T3-E1 cells. J Bone Miner Res 2002; 17:1190–1199.PubMedCrossRefGoogle Scholar
  71. 70.
    Saygin NE, Tokiyasu Y, Giannobile WV, Somerman MJ. Growth factors regulate expression of mineral associated genes in cementoblasts. J Periodontol 2000; 71:1591–1600.PubMedCrossRefGoogle Scholar
  72. 71.
    Fielding JW, Pyle RN, Jr., Fietti VG, Jr. Anterior cervical vertebral body resection and bone-grafting for benign and malignant tumors. A survey under the auspices of the Cervical Spine Research Society. J Bone Joint Surg Am 1979; 61:251–253.PubMedGoogle Scholar
  73. 72.
    Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 1974; 291:1041–1046.PubMedGoogle Scholar
  74. 73.
    Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop 2003; (415):S67–S74.PubMedCrossRefGoogle Scholar
  75. 74.
    Bennett A, McDonald AM, Simpson JS, Stamford IF. Breast cancer, prostaglandins, and bone metastases. Lancet 1975; 1:1218–1220.PubMedCrossRefGoogle Scholar
  76. 75.
    Greaves M, Ibbotson KJ, Atkins D, Martin TJ. Prostaglandins as mediators of bone resorption in renal and breast tumours. Clin Sci (Lond) 1980; 58:201–210.Google Scholar
  77. 76.
    Nimberg RB, Humphries DE, Lloyd WS, et al. Isolation of a bone-resorptive factor from human cancer ascites fluid. Cancer Res 1978; 38:1983–1989.PubMedGoogle Scholar
  78. 77.
    Galasko CS, Bennett A. Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins. Nature 1976; 263:508–510.PubMedCrossRefGoogle Scholar
  79. 78.
    Asdourian PL, Weidenbaum M, DeWald RL, Hammerberg KW, Ramsey RG. The pattern of vertebral involvement in metastatic vertebral breast cancer. Clin Orthop 1990; 250:164–170.PubMedGoogle Scholar
  80. 79.
    Braunstein EM, Kuhns LR. Computed tomographic demonstration of spinal metastases. Spine 1983; 8:912–915.PubMedCrossRefGoogle Scholar
  81. 80.
    Thompson JE, Keiller VH. Multiple skeletal metastases from cancer of the breast. Surg Gynecol Obstet 1924; 38:367–375.Google Scholar
  82. 81.
    Fujita T, Ueda Y, Kawahara N, Baba H, Tomita K. Local spread of metastatic vertebral tumors. A histologic study. Spine 1997; 22:1905–1912.PubMedCrossRefGoogle Scholar
  83. 82.
    Tomita K, Kawahara N, Kobayashi T, et al. Surgical strategy for spinal metastases. Spine 2001; 26:298–306.PubMedCrossRefGoogle Scholar
  84. 83.
    Tokuhashi Y, Matsuzaki H, Toriyama S, Kawano H, Ohsaka S. Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine 1990; 15:1110–1113.PubMedCrossRefGoogle Scholar
  85. 84.
    Tomita K, Kawahara N, Baba H, et al. Total en bloc spondylectomy. A new surgical technique for primary malignant vertebral tumors. Spine 1997; 22:324–333.PubMedCrossRefGoogle Scholar
  86. 85.
    Tomita K, Kawahara N, Baba H, et al. Total en bloc spondylectomy for solitary spinal metastases. Int Orthop 1994; 18:291–298.PubMedCrossRefGoogle Scholar
  87. 86.
    Findlay GF. The role of vertebral body collapse in the management of malignant spinal cord compression. J Neurol Neurosurg Psychiatry 1987; 50:151–154.PubMedGoogle Scholar
  88. 87.
    Fessler RG, Dietze DD, Jr., Millan MM, Peace D. Lateral parascapular extrapleural approach to the upper thoracic spine. J Neurosurg 1991; 75:349–355.PubMedCrossRefGoogle Scholar
  89. 88.
    Rompe JD, Eysel P, Hopf C, Heine J. Decompression/stabilization of the metastatic spine. Cotrel-Dubousset-Instrumentation in 50 patients. Acta Orthop Scand 1993; 64:3–8.PubMedGoogle Scholar
  90. 89.
    Sundaresan N, Choi IS, Hughes JE, Sachdev VP, Berenstein A. Treatment of spinal metastases from kidney cancer by presurgical embolization and resection. J Neurosurg 1990; 73:548–554.PubMedGoogle Scholar
  91. 90.
    Sundaresan N, DiGiacinto GV, Krol G, Hughes JE. Spondylectomy for malignant tumors of the spine. J Clin Oncol 1989; 7:1485–1491.PubMedGoogle Scholar
  92. 91.
    Sundaresan N, Galicich JH, Lane JM, Bains MS, McCormack P. Treatment of neoplastic epidural cord compression by vertebral body resection and stabilization. J Neurosurg 1985; 63:676–684.PubMedGoogle Scholar
  93. 92.
    Siegal T. Surgical Management of malignant epidural tumors compressing the spinal cord. In: Schmidek, ed. Operative Neurosurgical Techniques: Indications, Methods and Results. 3 ed. Philadelphia, PA: WB Saunders; 1995:1997–2005.Google Scholar

Copyright information

© Humana Press, Inc., Totowa, NJ 2006

Authors and Affiliations

  • Daisuke Togawa
    • 1
  • Kai-Uwe Lewandrowski
    • 2
  1. 1.The Cleveland Clinic Spine Institute and the Department of Orthopaedic SurgeryThe Cleveland Clinic FoundationCleveland
  2. 2.The Cleveland Clinic Spine InstituteThe Cleveland Clinic FoundationCleveland

Personalised recommendations